BENDECTIN Drug Patent Profile
✉ Email this page to a colleague
When do Bendectin patents expire, and what generic alternatives are available?
Bendectin is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in BENDECTIN is doxylamine succinate; pyridoxine hydrochloride. There are fourteen drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the doxylamine succinate; pyridoxine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Bendectin
A generic version of BENDECTIN was approved as doxylamine succinate; pyridoxine hydrochloride by ACTAVIS LABS FL INC on August 19th, 2016.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for BENDECTIN?
- What are the global sales for BENDECTIN?
- What is Average Wholesale Price for BENDECTIN?
Summary for BENDECTIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 147 |
| Patent Applications: | 1,429 |
| DailyMed Link: | BENDECTIN at DailyMed |
US Patents and Regulatory Information for BENDECTIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | BENDECTIN | doxylamine succinate; pyridoxine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 010598-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
